#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-9b170f74-f044-495f-b4b6-265a96f3b718: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-bc16bdb8-4c3c-4667-a1bf-78e4c1833420: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

Report Store Get Proposal

Home Blog Tag Macrogenics

MacroGenics

patent ductus arteriosus

Dec 11, 2018

Notizia

Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...

Read More...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles

Feb 12, 2025

Toll-like Receptors Agonist

TLR 7 and 8 Agonist

Gene Therapies Whitepaper

Toll-like Receptors Agonist

TLR 7 and 8 Agonist

Gene Therapies Whitepaper

Newsletter/Whitepaper